Australian Coral: Well Suited for Climate Change
Life’s not so bad for Australia’s coral reefs.
As the oceans heat up and the world’s temperature continues to rise (even despite our best efforts to green the planet), more than 1,000 kilometres of coral reef along Australia’s coastline are actually benefitting from the warmth – a finding that goes against what scientists predicted would happen, the Herald Sun reported.
In the latest Australian Institute of Marine Science study, 27 coral core samples from six locations were selected by researchers, who then determined the age of each sample. The results were quite surprising: the coral collected from the southern ocean region, for example, was found to have grown the most significantly, despite the fact that the water is coldest there.
Researchers pointed out, however, that the southern ocean region has experienced the greatest temperature increase.
"Those reefs have actually been able to take advantage of the warmer conditions," said Janice Lough, a senior AIMS research scientist who co-authored the study, to the Herald Sun.
SEE RELATED STORIES FROM THE WDM CONTENT NETWORK:
- Climate Change to Bring Heat, Bushfires to NSW
- Wind Farms May Be Affecting Australia's Weather
- Great Barrier Reef: A Street View
The results mirror those compiled through a study conducted by researchers at James Cook University, who studied the various corals that make up the Great Barrier Reef in order to figure out which species were more adaptable to the changing ocean temperature and acid levels.
Some corals were found to possess certain ‘zooanthellae’ cells such as “warm genes” that allow them to adapt to the rising temperature, while others were able to survive in the low-pH level “submarine springs.”
Researchers determined that while coral wasn’t going to go extinct due to climate change, the better-suited corals – typically the mound-shaped types over the branch-shaped variety – would likely end up dominating the reef’s landscape.
“Overall, it’s good news for coral, but we need to keep it in context,” said Emily Howells, a James Cook researcher on the project. “The overarching question is whether they can adapt at the same rate that the ocean temperature is rising.”
Seo JungJin: Who is EY’s World Entrepreneur of 2021?
Seo JungJin, founder of biopharma firm Celltrion, which most recently developed an antibody treatment for COVID-19, has been named the EY World Entrepreneur of the Year 2021, becoming the first South Korean in the award’s 21-year history.
Regarded as one of the world’s most prestigious business awards program for entrepreneurs, the EY Entrepreneur of the Year celebrates visionary and innovative leaders from across 60 countries who are transforming the world and fostering growth.
JungJin, who is now honoroary chairman of Celltrion Group, was up against a worthy cast of entrepreneurial competitors, taking the crown from among 45 award winners across 38 countries and territories.
Speaking during the virtual event, JungJin described his own interpretation of entrepreneurship as something that brings together “a group of people toward a common vision, embracing challenges as opportunities and committing oneself to contribute to the greater good”.
Why was JungJin crowned King Entrepreneur?
A South Korean native and now 63 years of age, JungJin founded biopharmaceutical firm Celltrion in 2003. In the nearly two decades since its founding, Celltrion has lived up to its goal of advancing health and welfare for all by developing ground-breaking drugs to treat autoimmune disease, various forms of cancer and, most recently, COVID-19.
The company, which JungJin started with just US$45,000 and five of his colleagues, has since growth to more than 2,1000 employees with sales permits in more than 90 countries and revenues exceeding US$1.69bn.
According to the panel, JungJin’s story is a shining example of the power of an unstoppable entrepreneur to change the world with the pandel moved by both his incredible story and his purpose-driven leadership, innovative mindset and entrepreneurial spirit.
Described by the chair of the EY judging panel Rosaleen Blair as “representing everything an unstoppable should be” from taking on the world’s biggest health care challenges to consistently creating long-term value for his company, JungJin’s story is one of incredible tenacity and perseverance that the judging panel felt most represented the entrepreneurial spirit.
“He’s taken breathtaking risks, both personal and professional, to found Celltrion and grow it into one of the world’s leading biopharmaceutical companies,” says Stasia Mitchell, EY Global Entrepreneurship Leader. “His passion for creating affordable, life-saving health care and flair for tackling global problems has led to many treatments that have helped millions of people worldwide and was especially evident this past year through the creation of a COVID-19 antibody treatment.”
How did JungJin get there?
JungJin's entrepreneurial journey started at an early age when he worked as a taxi driver to get himself through Konkuk University in Seoul, South Korea. After studying industrial engineering, he rose through the ranks of Daewoo Motor Co. before losing his job amid the carmaker’s financial troubles following the 1997 Asian economic crisis.
Following this, JungJin started collaborating with colleagues to explore business opportunities in different industries, though none delivered lasting success. The turning point came after he attended a talk hosted by renowned scholars, which inspired him to focus on the biopharmaceutical sector.
And so he founded Celltrion with just US$45,000 of his savings. The launch of Remsima, credited with being the world's first antibody biosimilar, quickly moved Celltrion up the ranks of the country's fairly underdeveloped pharmaceutical sector. Celltrion followed this success with the launch of drugs for breast cancer and lymphoma that today are being used worldwide.
With ambitions to be the world’s first in different areas, Celltrion has pioneered numerous uncharted areas to great success over the past two decades, most recently responding to the global pandemic by successfully developing an antibody treatment for COVID-19 and working to ensure a timely supply of the safe and effective treatment.
“When I first started, my vision was to help patients gain access to safe, effective and affordable medicines and thereby enhance the quality of people’s lives,” explains JungJin. “The success of Celltrion has enabled me to expand on this while finding new ways to fuel my entrepreneurial drive.”